Fexofenadine (180mg)
Allegix 180 mg Tablet is used in the treatment of allergic conditions. It is used to relieve the symptoms that occur with seasonal allergic rhinitis such as sneezing, itchy, runny or blocked nose and itchy, red and watery eyes.
1 Strip of 6 Tablet
Image shown is a representation and may slightly vary from the actual product. Every effort is made to maintain accuracy of all information displayed.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Allegix 180 mg Tablet is to be taken empty stomach.
Allegix 180 mg Tablet is an antihistaminic medication. It treats allergy symptoms such as such as itching, swelling, and rashes by blocking the effects of a chemical messenger (histamine) in the body.
Related Warnings
Allegix 180 mg Tablet may cause excessive drowsiness and calmness with alcohol.
Allegix 180 mg Tablet may be unsafe to use during pregnancy.
Animal studies have shown adverse effects on the foetus, however, there are limited human studies. The benefits from use in pregnant women may be acceptable despite the risk. Please consult your doctor.
Allegix 180 mg Tablet is safe to use during lactation. Human studies have shown that either the drug does not pass into the breastmilk in significant amount or is not expected to cause toxicity to the baby.
Because of low milk levels and lack of sleepiness, use of Allegix 180 mg Tablet would not be expected to cause any adverse effects in breastfed babies.
Allegix 180 mg Tablet does not usually affect your ability to drive.
Allegix 180 mg Tablet should be used with caution in patients with kidney disease. Dose adjustment of Allegix 180 mg Tablet may be needed. Please consult your doctor.
May cause excessive sleepiness in patients with end stage kidney disease.
Allegix 180 mg Tablet is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Allegix 180 mg Tablet may not be needed in these patients. Please consult your doctor.
